The 2021 WHO Classification of Primary CNS Tumors identifies TERT promoter mutations as crucial diagnostic markers for CNS tumors, particularly in oligodendroglioma, glioblastoma, and meningioma, with a high mutation frequency of 70% in glioblastomas [57]. The gene discussed is TERT; the disease is glioblastoma.